Thrombophilia and Thrombosis in Thrombotic Thrombocytopenic Purpura

ABSTRACT

Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder characterized by microangiopathic hemolytic anemia and thrombocytopenia often accompanied by microvascular ischemia, which may manifest as sensorimotor signs, visual changes, renal impairment, cardiac ischemia, and abdominal pain, depending on the organs affected. Until a few decades ago, TTP remained an almost universally fatal disorder. The introduction of plasma exchange therapy (PE) with replacement of fresh frozen plasma has improved the survival of patients with acute TTP dramatically from less than 10% to approximately 80 to 90% and is now considered the therapy of choice. During the last decade, the understanding of the pathophysiology of thrombotic microangiopathies, especially TTP, has increased considerably. The clinical features of thrombotic sequelae in TTP are diverse and usually secondary to microvascular thrombosis. Clinical and laboratory evidence for disruption of primary and secondary hemostasis, the role of endothelial integrity and fibrinolysis, the relevance of large vessel thrombosis, and the prevalence of thrombophilic states in TTP are discussed in this review. In summary, although the syndrome of TTP can sometimes be confused with other thrombotic diatheses, it is clear that the phenomenon of thrombosis in TTP appears to be distinctly different, both biologically and clinically, from other causes of microangiopathy and/or antibody-mediated thrombosis. Traditional anticoagulant and antiplatelet strategies are generally not effective in patients with TTP, despite the predominance of thrombotic manifestations, and common prothrombotic polymorphisms detected in patients with venous thromboembolism are seldom present.

KEYWORDS

Thrombophilia - hypercoagulable state - thrombosis - thrombotic thrombocytopenic purpura (TTP) - microangiopathy

REFERENCES

• 1 Amorosi E L, Ultmann J E. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature.  Medicine (Baltimore). 1966;  45 139-159
• 2 Rock G A, Shumak K H, Buskard N A et al.. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.  N Engl J Med. 1991;  325 393-397
• 3 Bell W R, Braine H G, Ness P M, Kickler T S. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.  N Engl J Med. 1991;  325 398-403
• 4 George J N. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.  Blood. 2000;  96 1223-1229
• 5 Hsu H W, Belfort M A, Vernino S, Moake J L, Moise Jr K J. Postpartum thrombotic thrombocytopenic purpura complicated by Budd-Chiari syndrome.  Obstet Gynecol. 1995;  85(5 pt 2) 839-843
• 6 Schwartz S G, McPherson A R, Mieler W F, Sessoms S L, Moake J L, Holz E R. Bilateral combined occlusion of the central retinal artery and vein secondary to thrombotic thrombocytopenic purpura.  Arch Ophthalmol. 2000;  118 1304-1305
• 7 Mohamed M D, McKibbin M A. Further considerations of retinopathy with renal failure.  Br J Ophthalmol. 2003;  87 659
• 8 Rizvi M A, Vesely S K, George J N et al.. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome.  Transfusion. 2000;  40 896-901
• 9 Downes K A, Yomtovian R, Tsai H M, Silver B, Rutherford C, Sarode R. Relapsed thrombotic thrombocytopenic purpura presenting as an acute cerebrovascular accident.  J Clin Apher. 2004;  19 86-89
• 10 Rinkel G J, Wijdicks E F, Hene R J. Stroke in relapsing thrombotic thrombocytopenic purpura.  Stroke. 1991;  22 1087-1089
• 11 Dhawan S, Tak T. Myocardial infarction in a patient with thrombotic thrombocytopenic purpura.  Int J Cardiol. 2004;  95 339-341
• 12 Ibernon M, Moreso F, Carreras L et al.. Thrombotic thrombocytopenic purpura with severe large artery branch involvement.  Nephrol Dial Transplant. 2005;  20 467-468
• 13 Kelly P J, McDonald C T, O'Neill G, Thomas C, Niles J, Rordorf G. Middle cerebral artery main stem thrombosis in two siblings with familial thrombotic thrombocytopenic purpura.  Neurology. 1998;  50 1157-1160
• 14 Moake J L. Thrombotic microangiopathies.  N Engl J Med. 2002;  347 589-600
• 15 Asherson R A, Cervera R, Piette J-C et al.. Catastrophic antiphospholipid syndrome. Clues to the pathogenesis from a series of 80 patients.  Medicine (Baltimore). 2001;  80 355-377
• 16 Espinosa G, Bucciarelli S, Cervera R et al.. Thrombotic microangiopathic haemolytic anemia and antiphospholipid antibodies.  Ann Rheum Dis. 2004;  63 730-736
• 17 Sadler J E. Biochemistry and genetics of von Willebrand factor.  Annu Rev Biochem. 1998;  67 395-424
• 18 Moake J L, Rudy C K, Troll J H et al.. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.  N Engl J Med. 1982;  307 1432-1435
• 19 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.  Blood. 1996;  87 4223-4234
• 20 Tsai H M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion.  Blood. 1996;  87 4235-4244
• 21 Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family.  Blood. 2001;  98 1662-1666
• 22 Gerritsen H E, Robles R, Lämmle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease.  Blood. 2001;  98 1654-1661
• 23 Zheng X, Chung D, Takayama T K, Majerus E M, Sadler J E, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS-13), a metalloprotease involved in thrombotic thrombocytopenic purpura.  J Biol Chem. 2001;  276 41059-41063
• 24 Levy G G, Nichols W C, Lian E C et al.. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.  Nature. 2001;  413 488-494
• 25 Furlan M, Lämmle B. Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura.  Baillieres Clin Haematol. 1998;  11 509-514
• 26 Boon D M, Michiels J J, Tanghe H L, Kappers-Klunne M C. Heparin-induced thrombocytopenia with multiple cerebral infarctions simulating thrombotic thrombocytopenic purpura. A case report.  Angiology. 1996;  47 407-411
• 27 Jimenez J J, Jy W, Mauro L M, Horstman L L, Soderland C, Ahn Y S. Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activation.  Br J Haematol. 2003;  123 896-902
• 28 Tsai H M, Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.  N Engl J Med. 1998;  339 1585-1594
• 29 Padilla A, Moake J L, Bernardo A et al.. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface.  Blood. 2004;  103 2150-2156
• 30 Wright J F, Wang H, Hornstein A et al.. Characterization of platelet glycoproteins and platelet/endothelial cell antibodies in patients with thrombotic thrombocytopenic purpura.  Br J Haematol. 1999;  107 546-555
• 31 Raife T J, Lentz S R, Atkinson B S, Vesely S K, Hessner M J. Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity.  Blood. 2002;  99 437-442
• 32 Wada H, Kaneko T, Ohiwa M et al.. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura.  Am J Hematol. 1993;  44 101-105
• 33 Wada H, Kaneko T, Ohiwa M et al.. Plasma cytokine levels in thrombotic thrombocytopenic purpura.  Am J Hematol. 1992;  40 167-170
• 34 Ruiz-Torres M P, Casiraghi F, Galbusera M et al.. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies.  Thromb Haemost. 2005;  93 443-452
• 35 Watanabe R, Wada H, Sakakura M et al.. Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states.  Am J Hematol. 2000;  65 35-40
• 36 Takahashi H, Tatewaki W, Nakamura T, Hanano M, Wada K, Shibata A. Coagulation studies in thrombotic thrombocytopenic purpura, with special reference to von Willebrand factor and protein C.  Am J Hematol. 1989;  30 14-21
• 37 Kobayashi M, Wada H, Wakita Y et al.. Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura.  Thromb Haemost. 1995;  73 10-14
• 38 Watanabe R, Wada H, Miura Y et al.. Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura.  Clin Appl Thromb Hemost. 2001;  7 229-233
• 39 Kwaan H C, Gallo G, Potter E, Cutting H, Stanzler R. The nature of the vascular lesion in thrombotic thrombocytopenic purpura.  Ann Intern Med. 1968;  68 1169-1170
• 40 Yarranton H, Cohen H, Pavord S R, Benjamin S, Hagger D, Machin S J. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura.  Br J Haematol. 2003;  121 778-785
• 41 Rock G, Shumak K H, Sutton D M, Buskard N A, Nair R C. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group.  Br J Haematol. 1996;  94 383-386
• 42 Mori Y, Wada H, Okugawa Y et al.. Increased plasma thrombomodulin as a vascular endothelial cell marker in patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.  Clin Appl Thromb Hemost. 2001;  7 5-9
• 43 Manuelian T, Hellwage J, Meri S et al.. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome.  J Clin Invest. 2003;  111 1181-1190
• 44 Noris M, Bucchioni S, Galbusera M for the International Registry of Recurrent and Familial HUS/TTP et al. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement.  J Am Soc Nephrol. 2005;  16 1177-1183
• 45 Rampazzo P, Biasiolo A, Garin J et al.. Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins.  Thromb Haemost. 2001;  85 57-62
• 46 Goel N, Ortel T L, Bali D et al.. Familial antiphospholipid syndrome. Criteria for disease and evidence for autosomal dominant inheritance.  Arthritis Rheuma. 1999;  42 318-327
• 47 Flamholz R, Jeon H R, Baron J M, Baron B W. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses?.  J Clin Apher. 2000;  15 169-172
• 48 Yarranton H, Lawrie A S, Purdy G, Mackie I J, Machin S J. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura.  Transfus Med. 2004;  14 39-44